| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 28.98 | 0.92 (+3.28%) | 9.94 - 29.07 | 384.1 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 28.84 |
|---|---|
| Previous Close | 28.06 |
| Day's Range | 28.47 - 29.07 |
| Market Cap | 1.8B |
| Avg Volume (10 Day) | 446.1K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -2.01 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference
Business Wire - Tuesday 05/21/2013 4:00 PM ET
Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria
Business Wire - Friday 05/17/2013 8:00 AM ET
Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference
Business Wire - Wednesday 05/15/2013 4:00 PM ET
Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference
Business Wire - Wednesday 05/08/2013 4:00 PM ET
Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results
Business Wire - Monday 05/06/2013 4:00 PM ET
Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results
Business Wire - Monday 04/29/2013 4:00 PM ET
| ALNY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -21.43% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 27.81 |
| Company | Last | Change |
|---|---|---|
| Arena Pharmaceuticals Inc | 8.30 | +2.99% |
| ViroPharma Inc | 27.04 | +2.27% |
| Mannkind Corp | 6.55 | -4.38% |
| Questcor Pharmaceuticals Inc | 34.86 | -1.22% |
| Immunogen Inc | 17.89 | +0.85% |
Data is delayed by at least 15 min.